Professor
Andrew Roberts
AM FAA FAHMS
Andrew Roberts has conducted ground-breaking research that has delivered a novel drug for blood cancer patients. From concept, through laboratory testing and clinical trials he has been a pioneer in the development of BCL2 inhibitors, specifically the first-in-class drug, venetoclax. After initiating testing on human samples during drug design, Roberts led the first-in-human trial, before developing combination therapies and leading the first combination trials in leukaemia and lymphoma. Venetoclax is approved in Australia and internationally for chronic lymphocytic leukaemia, and for acute myeloid leukaemia in the USA.
Fields of research
32 BIOMEDICAL AND CLINICAL SCIENCES- 3202 CLINICAL SCIENCES
-
3211
ONCOLOGY AND CARCINOGENESIS
- 321106 Haematological Tumours
- 321108 Molecular Targets
For full list of research codes, please visit the ARC Website .
Expertise type
- Medical Sciences
- Apoptosis
- Cancer Biology
- Haematology
- Blood Cells
- Drug Mechanisms
Please contact fellowship@science.org.au to request any updates to the data.